不同参松养心胶囊用药方案治疗阵发性心房颤动有效性和安全性的网状Meta分析

Network Meta-analysis of Shensongyangxin Capsules Combined with Amiodarone for Paroxysmal Atrial Fibrillation

目的采用网状Meta分析评价不同参松养心胶囊(SSYX)用药方案治疗阵发性心房颤动的有效性和安全性。方法计算机检索Pub Med、CBM、CNKI、VIP、Wanfang数据库,时间从建库至2016年5月。结果共纳入29个研究,包括2 726例患者。网状Meta分析结果显示,SSYX联合胺碘酮组的有效性高于胺碘酮组、β受体阻滞剂组、常规治疗组、SSYX组(P<0.05),与普罗帕酮组、SSYX联合普罗帕酮组、SSYX联合β受体阻滞剂组之间的差异无统计学意义。各SSYX治疗方案与对照组之间的不良事件发生率差异无统计学意义。不同SSYX治疗方案有效性的排序概率图显示参松养心胶囊联合胺碘酮的临床疗效最好(55%)。结论参松养心胶囊联合胺碘酮治疗阵发性房颤的有效性和安全性较好,值得临床参考。

OBJECTIVE To assess the efficacy and safety of shensongyangxin capsules（SSYX） combined with amiodarone for treating paroxysmal atrial fibrillation（PAF） by using network meta-analysis. METHODS The following databases were searched up to May 2016, including Pub Med, CBM, CNKI, VIP and Wanfang databases. After two reviewers independently extracted data, network meta-analysis was performed according to methods of Cochrane Collaboration. RESULTS Twenty-nine randomized controlled trials with 2 726 patients were included. Network meta-analysis showed that SSYX plus amiodarone was more effective compared with amiodarone, beta blocker, SSYX, routine treatment alone（P〈0.05）. However, there was no statistical difference between SSYX plus amiodarone and propafenone, SSYX plus propafenone, and SSYX plus beta blocker. When compared with control group, SSYX had no increase in the rate of adverse events. In addition, ranking results indicated that SSYX plus amiodarone was the first choice（55%）. CONCLUSION Available evidence could support the combination treatment of SSYX and amiodarone for PAF patients in clinic.